31 / 40
Evidencia en segunda línea:
Estudio 20050181
Peeters M, et al. Clin Cancer Res 2015;21:5469–79
WT RAS
Panitumumab
+ FOLFIRI
(n = 208)
FOLFIRI
(n = 213)
Median PFS, months
6.4
4.6
Hazard ratio
P-value
0.70
(95% CI, 0.54–0.91)
0.007
Median OS, months
16.2
13.9
Hazard ratio
P-value
0.81
(95% CI, 0.63–1.03)
0.08
ORR*, %
(n=204)
41
(34-48)
(n=207)
10
(6-15)
*
By central review.